Antithrombotic therapy for stable coronary artery disease: the difficult quest for the holy balance

Eur Heart J. 2016 Jan 21;37(4):409-11. doi: 10.1093/eurheartj/ehv471. Epub 2015 Oct 27.

Authors

Nicolas Danchin¹, Etienne Puymirat², François Schiele³

Affiliations

¹ Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, France; Université Paris-Descartes, France; INSERM U970, Paris, France nicolasdanchin@yahoo.fr.
² Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, France; Université Paris-Descartes, France; INSERM U970, Paris, France.
³ Centre Hospitalier Universitaire Jean Minjoz, France; Université de Franche-Comté, France.

PMID: 26508161
DOI: 10.1093/eurheartj/ehv471

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anticoagulants / therapeutic use
Coronary Artery Disease / drug therapy*
Fibrinolytic Agents / therapeutic use*
Humans
Platelet Aggregation Inhibitors / therapeutic use
Ticlopidine / therapeutic use

Substances

Anticoagulants
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Ticlopidine